
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6171027/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study. International Immunopharmacology, 2022, 107, 108709.	1.7	3
2	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. Stroke, 2022, 53, 2620-2627.	1.0	28
3	The CALL Score for Predicting Outcomes in Patients With COVID-19. Clinical Infectious Diseases, 2021, 72, 182-183.	2.9	34
4	Interleukinâ€6 added to <scp>CALL</scp> score better predicts the prognosis of COVIDâ€19 patients. Internal Medicine Journal, 2021, 51, 146-147.	0.5	3
5	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke, 2021, 52, 1450-1454.	1.0	7
6	Ultrasound-guided diagnosis of an uncommon stroke: A case of giant cell arteritis. Journal of the Neurological Sciences, 2021, 429, 119694.	0.3	0
7	Management of oral anticoagulation in very old patients with non valvular atrial fibrillation related acute ischemic stroke. Journal of Thrombosis and Thrombolysis, 2020, 49, 86-93.	1.0	7
8	Age-related burden and characteristics of embolic stroke of undetermined source in the real world clinical practice. Journal of Thrombosis and Thrombolysis, 2020, 49, 75-85.	1.0	10
9	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. European Stroke Journal, 2020, 5, 374-383.	2.7	6
10	Prognostic determinants in patients with non traumatic intracerebral hemorrhage: a real life report. Acta Clinica Belgica, 2020, 76, 1-8.	0.5	2
11	Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study. Infectious Diseases, 2020, 52, 675-677.	1.4	31
12	Anticoagulation in the early phase of non-valvular atrial fibrillation-related acute ischemic stroke: where do we stand?. Italian Journal of Medicine, 2019, 13, 24-31.	0.2	0
13	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke, 2019, 50, 2168-2174.	1.0	59
14	Direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: focus on real life studies. Journal of Thrombosis and Thrombolysis, 2019, 47, 292-300.	1.0	6
15	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Data in Brief, 2018, 17, 830-836.	0.5	5
16	Confidence in the Use of Direct Oral Anticoagulants in the Acute Phase of Nonvalvular Atrial Fibrillation–Related Ischemic Stroke Over the Years: A Real-World Single-Center Study. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 76-82.	0.7	7
17	Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study. Open Heart, 2018, 5, e000837.	0.9	6
18	Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence. Thrombosis Research, 2018, 172, 165-168.	0.8	1

#	Article	IF	CITATIONS
19	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. International Journal of Cardiology, 2018, 264, 58-63.	0.8	69
20	On-Treatment Platelet Reactivity is a Predictor of Adverse Events in Peripheral Artery Disease Patients Undergoing Percutaneous Angioplasty. European Journal of Vascular and Endovascular Surgery, 2018, 56, 545-552.	0.8	10
21	Direct oral anticoagulants in the early phase of nonâ€valvular atrial fibrillationâ€related ischemic stroke in very old patients undergoing systemic thrombolysis and/or mechanical thrombectomy. Geriatrics and Gerontology International, 2018, 18, 1304-1305.	0.7	3
22	Liver dysfunction as predictor of prognosis in patients with amyloidosis: utility of the Model for End-stage Liver disease (MELD) scoring system. Internal and Emergency Medicine, 2017, 12, 23-30.	1.0	3
23	The Val142lle transthyretin cardiac amyloidosis. Journal of Cardiovascular Medicine, 2016, 17, 122-125.	0.6	27
24	Different NT-proBNP circulating levels for different types of cardiac amyloidosis. Journal of Cardiovascular Medicine, 2016, 17, 810-817.	0.6	22
25	Sharing data of clinical trials. European Journal of Internal Medicine, 2016, 33, e25-e26.	1.0	0
26	High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI. European Journal of Internal Medicine, 2016, 30, 49-54.	1.0	17
27	Searching for a common mechanism for placenta-mediated pregnancy complications and cardiovascular disease: role of lipoprotein(a). Fertility and Sterility, 2016, 105, 1287-1293.e3.	0.5	13
28	On-treatment platelet reactivity: State of the art and perspectives. Vascular Pharmacology, 2016, 77, 8-18.	1.0	19
29	Echocardiographic and Biohumoral Characteristics in Patients With <scp>AL</scp> and <scp>TTR</scp> Amyloidosis at Diagnosis. Clinical Cardiology, 2015, 38, 69-75.	0.7	32
30	The Val142Ile transthyretin cardiac amyloidosis: more than an Afro-American pathogenic variant. Journal of Community Hospital Internal Medicine Perspectives, 2015, 5, 26931.	0.4	5
31	The platypnea-orthodeoxia syndrome: an unusual case of dyspnea. Internal and Emergency Medicine, 2015, 10, 535-536.	1.0	1
32	Non-traumatic splenic rupture on dual antiplatelet therapy with aspirin and ticagrelor after stenting for acute coronary syndrome. Journal of Cardiology Cases, 2015, 12, 65-67.	0.2	7
33	Biohumoral markers as predictor of right ventricular dysfunction in AL Amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 97-102.	1.4	11
34	Central nervous system hemangiopericytoma with bone and lung metastases: a case report. Internal and Emergency Medicine, 2014, 9, 349-350.	1.0	1
35	Hypokalemia-induced rhabdomyolysis. Internal and Emergency Medicine, 2014, 9, 487-488.	1.0	15
36	Residual perfusion defects in patients with pulmonary embolism are related to impaired fibrinolytic capacity. Thrombosis Research, 2014, 134, 737-741.	0.8	18

#	Article	IF	CITATIONS
37	A Case of Persistent Hiccup after Laparoscopic Cholecystectomy. Case Reports in Surgery, 2013, 2013, 1-4.	0.2	1
38	Fibrinolytic inhibitors and fibrin characteristics determine a hypofibrinolytic state in patients with pulmonary embolism. Thrombosis and Haemostasis, 2013, 109, 565-567.	1.8	6
39	Risk of recurrence in patients with pulmonary embolism: Predictive role of D-dimer and of residual perfusion defects on lung scintigraphy. Thrombosis and Haemostasis, 2013, 109, 181-186.	1.8	29
40	The Thrombophilic Pattern of Different Clinical Manifestations of Venous Thromboembolism: A Survey of 443 Cases of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2012, 38, 230-234.	1,5	18
41	Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Thrombosis and Haemostasis, 2012, 107, 1100-1106.	1.8	30
42	Risk of bleeding in low-risk atrial fibrillation patients on warfarin waiting for elective cardioversion. Thrombosis Research, 2012, 129, 588-590.	0.8	1
43	Incidence and characteristics of asymptomatic distal deep vein thrombosis unexpectedly found at admission in an Internal Medicine setting. Thrombosis Research, 2012, 130, 591-595.	0.8	15
44	Longâ€ŧerm outcomes of patients with cerebral vein thrombosis: a multicenter study. Journal of Thrombosis and Haemostasis, 2012, 10, 1297-1302.	1.9	129
45	Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: A prospective multicenter cohort study. American Journal of Hematology, 2012, 87, 384-387.	2.0	25
46	Bleeding and Stroke Risk in a Real-world Prospective Primary Prevention Cohort of Patients With Atrial Fibrillation. Chest, 2011, 140, 918-924.	0.4	29
47	Stroke Risk Stratification in a "Real-World―Elderly Anticoagulated Atrial Fibrillation Population. Journal of Cardiovascular Electrophysiology, 2011, 22, 25-30.	0.8	63
48	Retinal vein occlusions: a review for the internist. Internal and Emergency Medicine, 2011, 6, 307-314.	1.0	55
49	Lack of activation of renal functional reserve predicts the risk of significant renal involvement in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 1963-1967.	0.5	29
50	When and how is possible hemostatic therapy in non anticoagulant-associated intracerebral haemorrhage. Reviews in Health Care, 2011, 2, 87-91.	0.1	0
51	Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2010, 30, 294-299.	1.0	90
52	Fibrin Resistance to Lysis in Patients with Pulmonary Hypertension Other Than Thromboembolic. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 992-996.	2.5	60
53	Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thrombosis and Haemostasis, 2009, 101, 938-942.	1.8	91
54	Stroke risk in atrial fibrillation patients on warfarin. Thrombosis and Haemostasis, 2009, 101, 367-372.	1.8	48

#	Article	IF	CITATIONS
55	Different Models for Oral Anticoagulation Management May Be Applied Provided That Minimal Assistance Criteria Are Fulfilled: An Italian Experience. Seminars in Thrombosis and Hemostasis, 2009, 35, 568-573.	1.5	2
56	The Role of D-dimer Testing in Patients with Suspected Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2009, 35, 050-059.	1.5	49
57	Bleeding Risk During Oral Anticoagulation in Atrial Fibrillation Patients Older Than 80 Years. Journal of the American College of Cardiology, 2009, 54, 999-1002.	1.2	115
58	Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thrombosis and Haemostasis, 2009, 101, 367-72.	1.8	14
59	Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thrombosis and Haemostasis, 2009, 101, 938-42.	1.8	33
60	New-onset type 1 diabetes mellitus triggered by SARS-CoV-2 infection in a patient with Hashimoto thyroiditis: a case report. Italian Journal of Medicine, 0, , .	0.2	0
61	Efficacy and safety of edoxaban in cancer-associated venous thromboembolism: a real world retrospective study TH Open, 0, 0, .	0.7	1